AlenCiken

Sale of Manufacturing Operations and Global Supply Agreement

NASDAQ:ACOR   None
Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into "At The Market" Offering Agreement

$80 million up-front payment will substantially increase cash balance

Sale, restructuring and other operating expense reductions will reduce annual operating expenses by approximately $40 million

Total 2021 non-GAAP operating expense guidance expected to be $130-$140 million1

At The Market (ATM) offering allows the sale of common stock at aggregate value up to $15.25 million

Supply agreement will ensure uninterrupted supply of INBRIJA (levodopa inhalation powder) to people with Parkinson’s

finance.yahoo.com/ne...-sale-120000011.html stock


Отказ от ответственности

Все виды контента, которые вы можете увидеть на TradingView, не являются финансовыми, инвестиционными, торговыми или любыми другими рекомендациями. Мы не предоставляем советы по покупке и продаже активов. Подробнее — в Условиях использования TradingView.